Sechat - Notícias sobre a cannabis medicinal e cânhamo industrial

According to Filipe Campos, from Close-Up International, the market could expand even further with rule updates and increased medical adherence

On Deusa Cast, lawyer Larissa Meneghel details how the five-year deadline set forth in RDC-327 for clinical cannabis research works and comments on the renewal proposal under review by Anvisa

With the revision of RDC 327/2019, compounding pharmacies gain space in the discussion on medicinal cannabis

Paula Scanapieco, commercial manager at Mile Express, explains on Deusa Cast how RDC 660 ensures access for Brazilian patients to cannabis medications through international logistics

Paula Scanapieco, commercial manager at Mile Express, explains on Deusa Cast how RDC 660 ensures access for Brazilian patients to cannabis medications through international logistics

In Deusa Cast, experts discuss the possibility of storing cannabis-based products in Brazil. Regulatory advances, legal obstacles, and logistical impacts were debated in light of RDCs 660 and 327

In Deusa Cast, experts discuss the possibility of storing cannabis-based products in Brazil. Regulatory advances, legal hurdles, and logistical impacts were debated in light of RDCs 660 and 327

Curitiba welcomes its first exclusive medicinal cannabis pharmacy, in a market that grew from R$ 38.5 million in 2022 to R$ 237.8 million in 2025, while Paraná accounts for only 2.4% of sales, indicating great potential in the state with 11 million inhabitants

Pharmaceutical company Ephar has obtained registration for its Cannabidiol in two concentrations, 50 mg/mL and 100 mg/mL, which will be marketed in a low THC content drop solution

Cannten's extract with 71.33 mg/mL expands medicinal treatment options in the country and receives authorization for commercialization

Endogen's extract expands the portfolio of options for medicinal treatments and already has sanitary authorization for commercialization

Live broadcast will be held on the Agency's YouTube channel; board will have a strategic role in topics such as cannabis regulation in Brazil

The President emphasized the responsibility of the appointees and reinforced the importance of the agencies for the country's development

The event brings together experts, companies, and authorities to discuss regulatory advances, research, and innovation in cannabis-based therapies, connecting the entire public and private sector

With applications ranging from the pharmaceutical industry to construction, the sector is being structured with machinery, research, and investments, and is expected to grow even before the definitive regulation of cultivation in Brazil; the consultant discussed the topic during an interview at Andav 2025

Published by Anvisa, new resolution expands the scope of the network of analytical laboratories and reinforces the quality control of cannabis-based products in the country

Learn about the differences between CBD and THC, their therapeutic uses in various diseases, and understand the legal landscape of medical cannabis in Brazil, which is advancing with regulations that expand safe access for thousands of patients

The safety and efficacy of cannabis-based products depend on an integrated chain involving chemists, biomedicals, pharmacists, and doctors — professionals who ensure, at each stage, the quality, stability, and trust in patient treatment

The largest strategic meeting on medical cannabis and hemp in Brazil takes place in São Paulo, bringing together researchers, entrepreneurs, and professionals who are shaping the country's green future

During the 4th Brazilian Medicinal Cannabis Congress, the president of Sindusfarma emphasized that only clear and responsible regulation can ensure quality, trust, and safe access to plant-derived products.